Unproven and unapproved treatments in Australia

Unproven treatments have not undergone rigorous testing for their safety and effectiveness. There is one medication approved for treatment of MND in Australia – riluzole (sold as Rilutek™ or APO-Riluzole). 

This collection of FAQ sheets about MND treatments is designed to assist people living with MND to make informed decisions about their care and treatment. People living with MND are encouraged to discuss any therapies they hear about with their neurologist, GP or care team. 

edaravone molecular structure


In 2015, regulatory bodies approved edaravone to treat people with MND in Japan and South Korea. Subsequently, MT Pharma America submitted an application to the FDA for regulatory approval in the US. This application was approved by the FDA on 5 May 2017. Mitsubishi Tanabe Japan is responsible for making an application to the Therapeutic Goods Administration (TGA) to approve edaravone for the treatment of MND in Australia. As yet no application has been made. More about edaravone



News stories on access to and use of medicinal cannabis often capture the interest of people living with MND. There are many online claims that treatments derived from cannabis could slow progression or relieve symptoms for people living with MND; however, currently there is limited evidence or research supporting these claims. More on cannabis and MND

Proud member of:

International Alliance of ALS/MND Associations

ACNC Registered Charity


MND Australia would like to advise Aboriginal and Torres Strait Islander users that this website may contain images or names of deceased persons.